News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 644 results
April 2011
-
Media ReleaseNovartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis showsGilenya delayed the progression of disability both for patients who were previously treated for their MS and for patients who had not received prior treatment11 scientific abstracts on Gilenya…
-
Media ReleaseNovartis therapy Gilenya™ reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows
March 2011
-
Media ReleaseFDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPDPhase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149[1]COPD is a progressive and life-threatening lung…
-
Media ReleaseFDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD
January 2011
-
Media ReleaseImportant Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep ProductsEast Hanover, NJ, January 10, 2011 – Novartis Pharmaceuticals Corporation (Novartis) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks…
-
Media ReleaseImportant Information for Extavia® (interferon beta 1-b) Patients Regarding Triad Group's Alcohol Prep Products
December 2010
-
Media ReleaseNovartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications- In a clinical trial, Amturnide demonstrated significantly greater reductions in blood pressure compared to all dual combinations of its components- Amturnide combines the only approved direct renin…
-
Media ReleaseNovartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
-
Media ReleaseLonger-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CMLEAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the…
-
Media ReleaseLonger-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML
Pagination
- ‹ Previous page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- …
- 54
- › Next page